Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 11,562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 31, 2026, 2:14 AM EDT
Recruiting Phase 3 Interventional

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Ibrutinib, Acalabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
49
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Active, not recruiting No phase listed Observational

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180
View directory record Official record
Conditions
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
Interventions
Skin punch biopsy, Peripheral blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

NCT00002946
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 31, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

NCT01130688
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Zileuton
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 31, 2026, 2:14 AM EDT
Active, not recruiting Not applicable Interventional

Pediatric Powered Wheelchair Standing Devices: An Exploratory Study

NCT05117827
View directory record Official record
Conditions
Cerebral Palsy, Spinal Muscular Atrophy, Spinal Cord Injuries, Spina Bifida, Development Delay, Genetic Disease
Interventions
Power Wheelchair Standing Device
Device
Lead sponsor
Grand Valley State University
Other
Eligibility
5 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Tafasitamab, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Irvine, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00089154
View directory record Official record
Conditions
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
apolizumab, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 31, 2026, 2:14 AM EDT
Not listed No phase listed Observational

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

NCT06311123
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 2:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 31, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

A Study to Examine Anktiva for the Treatment of COVID-19.

NCT07123727
View directory record Official record
Conditions
Long COVID, Long COVID Syndrome, Long Covid 19
Interventions
Anktiva
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Recruiting Not applicable Interventional

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

NCT06299683
View directory record Official record
Conditions
Chronic Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Cystitis, Interstitial, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions
Psychosocial Treatment, Pelvic Floor Physical Therapy
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making (PREPARE)

NCT02072941
View directory record Official record
Conditions
Chronic Disease
Interventions
PREPARE Intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 31, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

NCT01675960
View directory record Official record
Conditions
Neurologically Impaired, Irritable Mood, Signs and Symptoms, Digestive, Sleeplessness, Chronic Pain
Interventions
Gabapentin, placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
1 Month to 16 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Participants With Chronic Rhinosinusitis

NCT03956862
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 31, 2026, 2:14 AM EDT
Completed No phase listed Observational Results available

Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury

NCT00628446
View directory record Official record
Conditions
Spinal Cord Injuries, Heart Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 31, 2026, 2:14 AM EDT
Not listed No phase listed Observational

Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

NCT02994303
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
1 Day to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Decatur, Georgia • Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 31, 2026, 2:14 AM EDT
Recruiting Not applicable Interventional

A Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE

NCT07125027
View directory record Official record
Conditions
Lumbosacral Radiculopathy, Sciatica, Chronic Low Back Pain With a Neuropathic Component, Radiculopathy Lumbar, Chronic Pain (Back / Neck)
Interventions
Move-MORE
Behavioral
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Team-Based Delivery of Care in Outpatient Settings

NCT03062670
View directory record Official record
Conditions
Chronic Disease
Interventions
Retreat
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
10
States / cities
Albert Lea, Minnesota • Austin, Minnesota • Cannon Falls, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 4 Interventional

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy

NCT02221583
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Astagraf XL, Prograf, Mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 31, 2026, 2:14 AM EDT
Not listed Not applicable Interventional

Peer Support for Post Intensive Care Syndrome Self-Management

NCT03788096
View directory record Official record
Conditions
Critical Illness, Sepsis, Shock, Septic, Shock, Respiratory Failure, Respiratory Distress Syndrome, Adult, Shock, Hypovolemic, Chronic Disease
Interventions
Peer Support with Motivational Interviewing, Usual Care Group
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 31, 2026, 2:14 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 31, 2026, 2:14 AM EDT